7 October 2022
EMA/CVMP/785090/2022
Committee for Veterinary Medicinal Products

Summary of opinion (post-authorisation)

Meloxoral

International non-proprietary name (INN): meloxicam

On 6 October 2022, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion, recommending the granting of an extension to the terms of the marketing authorisation for the veterinary medicinal product Meloxoral. The marketing authorisation holder for this veterinary medicinal product is Dechra Regulatory B.V.

Meloxoral is currently authorised as an oral suspension in two strengths - 0.5mg/ml for use in cats and 1.5mg/ml for use in dogs. It contains meloxicam, a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class (ATCvet code: QM01AC06). The extension concerns the addition of a new pharmaceutical form, chewable tablets, in three new strengths, 1.0mg, 2.5mg and 4.0mg, for use in dogs. The indication is:

Alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders.

Detailed conditions for the use of this product are described in the updated summary of product characteristics (SPC), for which an updated version reflecting the changes will be published in the revised European public assessment report (EPAR) and will be available in all official European Union languages after the extension to the marketing authorisation has been granted by the European Commission.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

© European Medicines Agency, 2022. Reproduction is authorised provided the source is acknowledged.